Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cambridge Nutritional SciencesFRA:RVKA Earnings Yield (Joel Greenblatt) % is 0.00% as of Sep. 2025. The stock has 3 warning signs investors should review. Among 850 Medical Devices & Instruments companies, Cambridge Nutritional Sciences ranks better than 99.41% on this metric.
Cambridge Nutritional Sciences's Enterprise Value for the quarter that ended in Sep. 2025 was €1.96 Mil.
Cambridge Nutritional Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was €1.67 Mil. Cambridge Nutritional Sciences's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2025 was 0.00%.
The historical rank and industry rank for Cambridge Nutritional Sciences's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:RVKA'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -216185.55 Med: -6.79 Max: 19425.7
Current: 118.96
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Cambridge Nutritional Sciences was 19425.70%. The lowest was -216185.55%. And the median was -6.79%.
FRA:RVKA's Earnings Yield (Joel Greenblatt) % is ranked better than 99.41% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 0.845
vs FRA:RVKA: 118.96
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Cambridge Nutritional Sciences's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Cambridge Nutritional Sciences's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambridge Nutritional Sciences Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cambridge Nutritional Sciences's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Cambridge Nutritional Sciences's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Cambridge Nutritional Sciencess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 0.00% mean?
Cambridge Nutritional Sciences (FRA:RVKA) has a Earnings Yield (Joel Greenblatt) % of 0.00% as of Sep. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Cambridge Nutritional Sciences and its competitors. According to the industry distribution chart, Cambridge Nutritional Sciences ranks #5 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 0.59999999999999%.
Is Cambridge Nutritional Sciences' Earnings Yield (Joel Greenblatt) % too high?
Cambridge Nutritional Sciences' current Earnings Yield (Joel Greenblatt) % is 0.00%. Based on the distribution chart, Cambridge Nutritional Sciences ranks #5 out of 850 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Cambridge Nutritional Sciences' Earnings Yield (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Cambridge Nutritional Sciences ranks #5 out of 850 companies for Earnings Yield (Joel Greenblatt) %. This places Cambridge Nutritional Sciences in the top 1% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 0.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.85, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Cambridge Nutritional Sciences and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambridge Nutritional Sciences's current Earnings Yield (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Nutritional Sciences (FRA:RVKA) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 27.5% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Cambridge Nutritional Sciences (FRA:RVKA), the current Earnings Yield (Joel Greenblatt) % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambridge Nutritional Sciences PLC is a medical diagnostics company specializing in the development, manufacture, and distribution of food sensitivity test kits. Its product portfolio includes tests designed to detect immune reactions to various foods, helping healthcare professionals and patients identify dietary and lifestyle changes to improve long-term health and wellbeing. The company operates in the United Kingdom and serves the customer base across various countries through laboratories and healthcare providers. It generates revenue by selling diagnostic kits and providing clinical analysis services centered on food sensitivity and gut health. The group has two reportable segments: Health and Nutrition; and Corporate. The Health and Nutrition segment generates majority revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RVKA has been successfully added to your 
